KRAS Neoantigen mRNA Vaccine(Abogen Biosciences)

N/A

Report date: 2026/05/06 20:02:28

Base Information

Drug NameKRAS Neoantigen mRNA Vaccine(Abogen Biosciences)
Drug Alias NameABO2102ABO-2102
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine > mRNA vaccine
Mechanisms of ActionImmunostimulantsV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog inhibitors
TargetsGTPase KRas
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesAbogen Biosciences Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAibo Biotechnology (Shanghai) Co LtdAbogen Biosciences Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungPancreatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A